Funding round

Magnitude Biosciences raises £1.3m

Magnitude Biosciences has raised £1.3m, announced on September 15, 2026. The company is Develops whole-organism drug screening platform using nematode worms and automation. The round was led by Northstar Ventures, with participation from Maven-managed regional funds, NPIF II – Maven Equity Finance, Finance Durham Fund, new angel investors.

Magnitude Biosciences raised £1.3 million to expand its VivoScan drug screening platform, commercial activity, equipment and team.

Company

Magnitude Biosciences

Amount

£1.3m (~$1.8M)

Round

Unknown

Sector

Drug discovery

Country

Announced

September 15, 2026

Track every raise, every day

This deal appeared in The Daily Raise, September 15, 2026. Get the next edition in your inbox.

Just raised too?

Turn your funding news into guaranteed media coverage while the momentum lasts.

Get featured